ACADIA Pharmaceuticals Inc. (ACAD) Social Stream



ACADIA Pharmaceuticals Inc. (ACAD): $16.40

0.66 (+4.19%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Featured Post From StockTwits About ACAD

$AXSM. Anyone who thinks a CRL is not coming might want to think again. Look at the following which happened I $acad two weeks before their CRL “Acadia announced Monday it had received a letter from the FDA on March 3 that “identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time.”
The news startled company executives, investors and analysts alike. The FDA stated that this notification is not a final decision on Nuplazid's new use. A still-shocked and obviously frustrated Acadia executive team laid out the scenario in an analyst call Monday afternoon after the announcement. They repeated several times that the drugmaker had received no additional information from the FDA, nor did the company have any idea of what the issue might be.” $IBB
homer212, published August 12, 2021

What Else are ACAD Traders Talking About?


Other tickers frequently mentioned alongside ACAD are AXSM and IBB.

Loading social stream, please wait...


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4495 seconds.